JP2012507997A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507997A5
JP2012507997A5 JP2011535119A JP2011535119A JP2012507997A5 JP 2012507997 A5 JP2012507997 A5 JP 2012507997A5 JP 2011535119 A JP2011535119 A JP 2011535119A JP 2011535119 A JP2011535119 A JP 2011535119A JP 2012507997 A5 JP2012507997 A5 JP 2012507997A5
Authority
JP
Japan
Prior art keywords
cell
derived
component
cells
immunoregulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011535119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507997A (ja
JP5745419B2 (ja
Filing date
Publication date
Priority claimed from GBGB0820397.8A external-priority patent/GB0820397D0/en
Application filed filed Critical
Publication of JP2012507997A publication Critical patent/JP2012507997A/ja
Publication of JP2012507997A5 publication Critical patent/JP2012507997A5/ja
Application granted granted Critical
Publication of JP5745419B2 publication Critical patent/JP5745419B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011535119A 2008-11-07 2009-11-06 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法 Active JP5745419B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0820397.8A GB0820397D0 (en) 2008-11-07 2008-11-07 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
GB0820397.8 2008-11-07
PCT/EP2009/064788 WO2010052313A1 (en) 2008-11-07 2009-11-06 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases

Publications (3)

Publication Number Publication Date
JP2012507997A JP2012507997A (ja) 2012-04-05
JP2012507997A5 true JP2012507997A5 (https=) 2012-12-20
JP5745419B2 JP5745419B2 (ja) 2015-07-08

Family

ID=40139550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011535119A Active JP5745419B2 (ja) 2008-11-07 2009-11-06 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法

Country Status (9)

Country Link
US (1) US9012220B2 (https=)
EP (1) EP2361261B1 (https=)
JP (1) JP5745419B2 (https=)
KR (1) KR101666692B1 (https=)
AU (1) AU2009312700B2 (https=)
CA (1) CA2742698C (https=)
ES (1) ES2479540T3 (https=)
GB (1) GB0820397D0 (https=)
WO (1) WO2010052313A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918615D0 (en) * 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
ES2479565T1 (es) * 2011-03-11 2014-08-20 Tigenix, S.A.U. Poblaciones celulares que tienen actividad immunoreguladora, método para el aislamiento y usos
EP3985106A1 (en) * 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population with enhanced therapeutic potential, method for obtaining of regulatory t cell population and the medical use of regulatory t cell population
EP3985105A1 (en) * 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population tregs with enhanced therapeutic potential, method for obtaining of conditioned tregs and the medical use of the tregs population

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029310A2 (en) * 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
EP1252897A4 (en) 2000-01-21 2003-07-30 Hisamitsu Pharmaceutical Co MEDICINES FOR GENE THERAPY
EP1501918A4 (en) * 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
EP1369114A1 (en) 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
ES2368152T3 (es) * 2005-07-01 2011-11-14 Txcell S.A. Obtención de células tr1 específicas de antígenos de los alimentos o de autoantígenos a partir de una población de leucocitos o pbmc.
EP3184630B1 (en) 2005-09-23 2019-07-17 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
CA2634072A1 (en) 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
US20090155311A1 (en) * 2006-01-07 2009-06-18 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
US20080155704A1 (en) * 2006-12-22 2008-06-26 King's College London Methods and Compositions for Determining in vivo Activity of BiP
WO2008100562A2 (en) 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
WO2009155477A1 (en) * 2008-06-19 2009-12-23 The Trustees Of The University Of Pennsylvania Inducible regulatory t-cell generation for hematopoietic transplants

Similar Documents

Publication Publication Date Title
Groeber et al. Skin tissue engineering—in vivo and in vitro applications
WO2012065027A3 (en) Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases
JP2014527821A5 (https=)
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
NZ612801A (en) Ultrasonic cavitation derived stromal or mesenchymal vascular extracts and cells derived therefrom obtained from adipose tissue and use thereof
AU2009240884A8 (en) Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
NZ608734A (en) Bone marrow derived cd271 precursor cells for cardiac repair
MY170013A (en) Methods and compositions for enhancing stem cell mobilization
EA201790025A1 (ru) Создание банка мезенхимальных стромальных клеток из объединенных мононуклеарных клеток нескольких доноров костного мозга
AR082411A1 (es) siRNA DIRIGIDO AL VEGFA Y METODOS DE TRATAMIENTO IN VIVO
ES2685319T3 (es) Generación de células marcapasos basada en factor de transcripción y métodos de uso de las mismas
JP2015159895A5 (https=)
WO2014093051A3 (en) Cardiac stem cells and methods of identifying and using the same
JP2010116400A5 (https=)
PH12014500301A1 (en) Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
WO2013056049A3 (en) Tubular prostheses
Kobielak et al. Skin and skin appendage regeneration
JP2012507997A5 (https=)
BR112016028561A2 (pt) composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo.
EP2623106A4 (en) Composition for regenerating follicle which contains cd36-expressing connective tissue sheath cells
ES2479540T1 (es) Células, construcciones de ácido nucleico, células que comprenden dichas construcciones y métodos que utilizan dichas células en el tratamiento de enfermedades
MX2021003798A (es) Terapia con celulas de placenta humana y celulas hematopoyeticas.
Aghakhani et al. The effect of education on anxiety and depression in patients with myocardial infarction in selected hospitals, Iran
WO2010047822A9 (en) Methods of using sdf-1 (cxcl12) as a diagnostic and mesenchymal stem cell (multipotent stromal cell)-specific therapeutic biomarker for the treatment of kidney injury and other major organs